Matches in Wikidata for { <http://www.wikidata.org/entity/Q61626183> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- Q61626183 description "article" @default.
- Q61626183 description "im Januar 2008 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61626183 description "wetenschappelijk artikel" @default.
- Q61626183 description "наукова стаття, опублікована в січні 2008" @default.
- Q61626183 description "հոդված" @default.
- Q61626183 name "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 name "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 type Item @default.
- Q61626183 label "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 label "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 prefLabel "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 prefLabel "Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity" @default.
- Q61626183 P1433 Q61626183-83297A05-3607-47A1-8D49-88F7A42A15E0 @default.
- Q61626183 P1476 Q61626183-834616A8-97B2-4FEB-9517-44008AD8277C @default.
- Q61626183 P2093 Q61626183-2822191E-A45B-4FA0-88AC-30E4F51CF3B2 @default.
- Q61626183 P2093 Q61626183-7DDACABF-5BB7-406C-97B4-0AF91D538006 @default.
- Q61626183 P2093 Q61626183-7F9CEDC3-B663-4A5B-8898-13B4C10EFBEF @default.
- Q61626183 P2093 Q61626183-9107CAEF-7046-4AEB-B748-5CCA3E626DD3 @default.
- Q61626183 P2093 Q61626183-AAB7811C-DE87-454D-99C7-E4B4821F2979 @default.
- Q61626183 P2093 Q61626183-AE2D9558-BF91-4AD1-AC56-A639662FA7BF @default.
- Q61626183 P2093 Q61626183-B29EF5FF-9720-4FC0-9EA5-7E42BE7543BE @default.
- Q61626183 P2093 Q61626183-B9A4888B-C508-4DBF-8101-DBE98A8BAB89 @default.
- Q61626183 P2093 Q61626183-BC465809-95BE-4A1C-93D8-673D3DFA32E1 @default.
- Q61626183 P304 Q61626183-70A76FA6-BD6D-45F7-9193-7345EF84859C @default.
- Q61626183 P31 Q61626183-ACDD4289-2811-4650-8E1D-2B219065F43E @default.
- Q61626183 P356 Q61626183-EFE3BFDB-B380-4860-B72A-C383C4C6D836 @default.
- Q61626183 P407 Q61626183-0AA01A6F-D9D4-46A4-9752-DF5568F733B3 @default.
- Q61626183 P433 Q61626183-72ED2E44-C279-47B0-B655-B80DC747F71F @default.
- Q61626183 P478 Q61626183-F1C20461-EF4D-4719-9C71-3B5DACA45214 @default.
- Q61626183 P50 Q61626183-3BF931C5-C403-4B32-BD99-FB95B78E7E0E @default.
- Q61626183 P50 Q61626183-4977A5A8-5705-4028-9423-6AC048C1CA4C @default.
- Q61626183 P50 Q61626183-9DC2EB46-DBCF-4926-B56E-39DFA162A042 @default.
- Q61626183 P50 Q61626183-CC7D41F6-F40F-4575-A71D-4F0C38B1F8A4 @default.
- Q61626183 P577 Q61626183-33C88C66-9372-4621-9E56-8D5240A7AD14 @default.
- Q61626183 P698 Q61626183-7E2F5791-4446-47FB-A7F8-3DC0946CF08A @default.
- Q61626183 P921 Q61626183-3B38F7F6-5C56-41DD-AFF3-80EE37569696 @default.
- Q61626183 P921 Q61626183-9531DDB0-9F82-4995-8165-5E16A5868D87 @default.
- Q61626183 P921 Q61626183-B913975A-D61E-406B-AB03-8182D91B0CDF @default.
- Q61626183 P921 Q61626183-C3260CC5-2020-4F69-A041-198A321A8320 @default.
- Q61626183 P356 1078-0432.CCR-07-1881 @default.
- Q61626183 P698 18172268 @default.
- Q61626183 P1433 Q332253 @default.
- Q61626183 P1476 "Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity" @default.
- Q61626183 P2093 "A Rob P M Valentijn" @default.
- Q61626183 P2093 "Amon R Wafelman" @default.
- Q61626183 P2093 "Annelies P G Vloon" @default.
- Q61626183 P2093 "Dorien M A Berends-van der Meer" @default.
- Q61626183 P2093 "Gert Jan Fleuren" @default.
- Q61626183 P2093 "Jaap Oostendorp" @default.
- Q61626183 P2093 "Margriet J G Lowik" @default.
- Q61626183 P2093 "Marij J P Welters" @default.
- Q61626183 P2093 "Rienk Offringa" @default.
- Q61626183 P304 "169-177" @default.
- Q61626183 P31 Q13442814 @default.
- Q61626183 P356 "10.1158/1078-0432.CCR-07-1881" @default.
- Q61626183 P407 Q1860 @default.
- Q61626183 P433 "1" @default.
- Q61626183 P478 "14" @default.
- Q61626183 P50 Q114408770 @default.
- Q61626183 P50 Q21552049 @default.
- Q61626183 P50 Q37828878 @default.
- Q61626183 P50 Q90315072 @default.
- Q61626183 P577 "2008-01-01T00:00:00Z" @default.
- Q61626183 P698 "18172268" @default.
- Q61626183 P921 Q1427096 @default.
- Q61626183 P921 Q160105 @default.
- Q61626183 P921 Q5452194 @default.
- Q61626183 P921 Q69461345 @default.